PD-1抑制剂治疗肝细胞癌疗效相关生物标志物的研究现状

Research status of biomarkers related to the efficacy of PD-1 inhibitors in the treatment of hepatocellular carcinoma

近年来免疫治疗在肝细胞癌辅助治疗领域取得了初步成果,而程序性死亡受体1(Programmed cell death-1,PD-1)抑制剂是目前的研究热点,然而其总反应率仍不尽如人意,因此目前急需寻找合适的生物标志物,来预测PD-1抑制剂治疗肝细胞癌患者的疗效,本文就PD-1抑制剂治疗肝细胞癌的相关生物标志物的研究进展进行综述。

In recent years,immunotherapy has achieved preliminary results in the field of adjuvant therapy for liver cancer.Programmed cell death-1(PD-1)inhibitors are the current research hotspot,but the overall response rate is still not high.As expected,there is an urgent need to find suitable biomarkers to predict the efficacy of PD-1 inhibitors in the treatment for liver cancer patients.This article reviews the research progress of PD-1 inhibitor therapy related biomarkers for hepatocellular carcinoma.